Last reviewed · How we verify
NCT07535528
Implant Placement Depth and Peri-Implant Tissue Outcomes
NA trial testing Subcrestal Implant Placement with Transmucosal Abutment and One Abutment-One Time Protocol in Dental Implant Placement in 80 participants. Not yet recruiting.
20 November 2026
Quick facts
| Lead sponsor | University of Valencia |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 15 May 2026 |
| Primary completion | 20 November 2026 |
| Estimated completion | 20 July 2027 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Subcrestal Implant Placement with Transmucosal Abutment and One Abutment-One Time Protocol
Conditions studied
- Dental Implant Placement — all drugs for Dental Implant Placement →
- Soft Tissue Management in Subcrestal Dental Implants — all drugs for Soft Tissue Management in Subcrestal Dental Implants →
- Marginal Bone Loss — all drugs for Marginal Bone Loss →
Sponsor
University of Valencia
Who can join
18 and older, any sex, with Dental Implant Placement or Soft Tissue Management in Subcrestal Dental Implants. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary aim of this randomized clinical trial is to evaluate the influence of subcrestal implant placement depth (-2 mm vs -4 mm) on peri-implant marginal bone level changes, including marginal bone loss and bone remodeling. Secondary outcomes include implant success, peri-implant probing depth (PPD), and bleeding on probing (BoP). Partially edentulous patients requiring fixed implant-supported prosthetic rehabilitation with two implants in posterior maxillary or mandibular regions will be included. Implants will be placed subcrestally at either -2 mm or -4 mm from the bone crest, following a submerged healing protocol. Allocation to insertion depth will be randomized. Marginal bone level changes will be assessed using standardized periapical radiographs at second-stage surgery, prosthesis placement, and at 1, 3, 6, and 12 months after functional loading. PPD and BoP will be recorded at the same time points.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07535528
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Valencia trials
Trials by the same sponsor.
- NCT07509281 — Peri-implant Tissues Changes for Different Abutment Shapes and Heights · NA · not yet recruiting
- NCT07471555 — Vascular Access and Intraosseus · NA · enrolling by invitation
- NCT07463066 — Long-Term Effectiveness of Pain Neuroscience Education in Women With Genito-Pelvic Pain/Penetration Disorder. · not yet recruiting
- NCT07419399 — Acute Effects of Radiofrequency Diathermy in Postpartum Women With Diastasis Abdominis · NA · recruiting
- NCT07504068 — Effects of Physical Exercise and a Nutritional Supplement on Body Composition, Metabolic Function, and Overall Health in · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07535528 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Valencia
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07535528.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing